Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.

Abstract

BACKGROUND:

Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies.

METHODS:

A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.

• Authors: Silvio Danese, Gionata Fiorino, Pierre Michetti
• Journal: Journal of Crohn's & colitis (J Crohns Colitis) Vol. 8 Issue 11 Pg. 1548-50 (Nov 2014) ISSN: 1876-4479 [Electronic] England
• PMID: 25008477 (Publication Type: Journal Article)
• Copyright: Copyright © 2014. Published by Elsevier B.V.

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Antibodies, Monoclonal
• Biosimilar Pharmaceuticals
• Infliximab

Topics

• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Attitude of Health Personnel
• Biosimilar Pharmaceuticals (therapeutic use)
• Colitis, Ulcerative (drug therapy)
• Crohn Disease (drug therapy)
• Drug Approval
• Drug Substitution
• Europe
• Gastroenterology
• Health Care Surveys
• Health Knowledge, Attitudes, Practice
• Humans
• Infliximab